Back
EHRA Premium Access

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks: ablation?

Session: Controversies in ventricular tachycardia (VT) ablation
Topic: Catheter Ablation of Arrhythmias
Speaker: Doctor M. Saba (London, GB)
Event: EHRA 2022

Congress Presentation

About the speaker

Doctor Magdi Saba

St George's University Hospital NHS Foundation Trust, London (United Kingdom of Great Britain & Northern Ireland)
7 presentations
1 follower

5 more presentations in this session

What will improve the results of VT ablation? Better mapping.

Speaker: Doctor P. Maury (Toulouse, FR)

Access
Slides
Video
Thumbnail

What will improve the results of VT ablation? Better technology.

Speaker: Professor J. Kautzner (Prague, CZ)

Access
Slides
Thumbnail

What will improve the results of VT ablation? - rebuttal and discussion.

Access
Thumbnail

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks: drugs?

Speaker: Professor A. Goette (Paderborn, DE)

Access
Slides
Thumbnail

Preferred first-line therapy for recurrent implantable cardioverter defibrillator shocks - rebuttal and discussion.

Access
Thumbnail

Access the full session

Controversies in ventricular tachycardia (VT) ablation

Speakers: Doctor M. Saba, Doctor P. Maury, Professor J. Kautzner, Professor A. Goette
Access
Thumbnail

About the event

Image

EHRA 2022

3 April - 5 April 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb